Several key investors in Amarin Corp., the Irish heart-drug developer with Stonington research operations, have cashed out for more than $45 million amid talk that Amarin is ripe for a partnership or takeover.
Last Thursday, London healthcare investor Abingworth LLP notified U.S. securities regulators of its sale of 2.3 million shares for $25.3 million, leaving it with 5.61 million shares, Seekingalpha.com reports.
In addition, Amarin director James Healy, who also is a partner in California's Sofinnova Venture Partners, filed papers declaring his sale of two million shares for $22 million, indirectly held by him via Sofinnova Venture Partners VII L.P. He has 5.51 million shares remaining.
Amarin recently won a U.S. patent and has filed with U.S. drug regulators for clearance to market an omega-3 fatty acid treatment to curb blood triglycerides harmful to the heart.
Seekingalpha.com said Tuesday that Wall Street "is rife with speculation of partnering possibilities, or even an outright acquisition at a stiff premium to current prices in the $11 to $12 range.''
Amarin stock traded mid-morning Tuesday at $9.90 a share, down 2 cents.